Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in HIV [clinicaltrials:NCT01601626]

Bio2RDF uri

Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in HIV [clinicaltrials:NCT01601626]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT01601626

Bio2RDF identifier

NCT01601626

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01601626

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01601626

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

471

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01601626 arm group 1ba43895ae9d878301b4d57cce22f132 [clinicaltrials_resource:NCT01601626/arm-group/1ba43895ae9d878301b4d57cce22f132]

NCT01601626 arm group 821581c2e07131e8c271ea2f5b156022 [clinicaltrials_resource:NCT01601626/arm-group/821581c2e07131e8c271ea2f5b156022]

NCT01601626 arm group 8927cbc07f806aeb0d1ae1d5fb06bee3 [clinicaltrials_resource:NCT01601626/arm-group/8927cbc07f806aeb0d1ae1d5fb06bee3]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:4c3cb4f1b6774aae040152e2cdb4237b

brief summary [clinicaltrials_vocabulary:brief-summary]

There is a rapidly-grow ...... accrual period 2 will begin.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Rifampin-Based Tuberculosis Tr ...... Tuberculosis Treatment in HIV

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C) 48 weeks [clinicaltrials_resource:0ccb59190801baf873e29b022989ac0b]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C) 48 weeks [clinicaltrials_resource:05d3dd1a61e5a3c371fd950ff53051fb]

Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C) 48 weeks [clinicaltrials_resource:09f3e49d305473acc39e906700a728de]

Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C) 48 weeks [clinicaltrials_resource:12834a68b294fca18539712287408f69]

Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C) 48 weeks [clinicaltrials_resource:142cd299ca76817343d9cb4e41d7f9cd]

Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C) 48 weeks [clinicaltrials_resource:18a2dc4553e5927bc2edcbf3c8e6d067]

Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C) 48 weeks [clinicaltrials_resource:1bcfba19e6c1dcbbf9a55485b2a5c0bf]

Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C) 48 weeks [clinicaltrials_resource:27a8b90da06068661d80f57b2948d64f]

Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C) 48 weeks [clinicaltrials_resource:2b6710ddd81e66799399ca07d6749d6d]

Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C) 48 weeks [clinicaltrials_resource:3ed4fa291fe5c61bee939edfda1b1789]

Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C) 48 weeks [clinicaltrials_resource:4e9ec28be6da91a5eb188da8ca998e74]

collaborator [clinicaltrials_vocabulary:collaborator]

AIDS Clinical Trials Group [clinicaltrials_resource:88246217bceed5c04807c4e7d6ad8b6b]

completion date [clinicaltrials_vocabulary:completion-date]

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01601626 [clinicaltrials_resource:09aab41d3e5ead7edc59e65e60073e74]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2012-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Lopinavir/Ritonavir [clinicaltrials_resource:01d043953136dee2cbe11444f71485c3]

Pyridoxine [clinicaltrials_resource:06aca0b977683fbf45d8e5c839d76472]

Isoniazid [clinicaltrials_resource:4f87e31fe1876f44e43d674c9e35d213]

Ethambutol [clinicaltrials_resource:8d31678cb1c6cb2ab34ed373b9f35016]

Rifabutin [clinicaltrials_resource:a4bea7001ad06d22771ad0dd9905fc67]

Rifampin [clinicaltrials_resource:c1cb552c3a7d6cf01d6839e497611ce3]

Pyrazinamide [clinicaltrials_resource:cf35f1c7c3e27ecbac4782fb7af7a706]

Raltegravir [clinicaltrials_resource:f205f377b1df3153a5d122771ea44cc3]

Lopinavir/Ritonavir [clinicaltrials_resource:f6b9afa0cbd71d37715f28192718a67b]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Rifabutin [clinicaltrials_resource:0873c60740b3276b384569eae4aec237]

Rifampin [clinicaltrials_resource:335c295bc30aeae46c3cf15b213d1df1]

Lopinavir [clinicaltrials_resource:6436a035d235ba79a2f88d2b45e2136f]

Pyrazinamide [clinicaltrials_resource:6ecbde4ff9ea3e5ab84cd7b21d4ccdf7]

Ritonavir [clinicaltrials_resource:7dc4e4f837ab8fba1b64636daa50e0d3]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

AIDS Clinical Trials Group [clinicaltrials_resource:88246217bceed5c04807c4e7d6ad8b6b]

location [clinicaltrials_vocabulary:location]

Instituto de Pesquisa Clinica Evandro Chagas (12101) [clinicaltrials_resource:ffa08e3a3507b27b6ea6e2e29f3f0793]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01601626

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Randomized, Phase 2b Study o ...... reatment for Active TB and HIV

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

ACTG A5290

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Constance A Benson, MD [clinicaltrials_resource:19d2643c307e69d9375304bd985d11b9]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United States: Federal Government [clinicaltrials_resource:3e6fb85f74da576ef06d30c2ff29436f]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

1U01AI068636

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

AIDS Clinical Trials Group [clinicaltrials_resource:88246217bceed5c04807c4e7d6ad8b6b]

start date [clinicaltrials_vocabulary:start-date]

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01601626 study design [clinicaltrials_resource:287fd3f1d4962f29eab36d9047b2ba9b]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01601626

verification date [clinicaltrials_vocabulary:verification-date]

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01601626

http://www.w3.org/2001/XMLSchema#string

title

Rifampin-Based Tuberculosis Tr ...... Tuberculosis Treatment in HIV

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Rifampin-Based Tuberculosis Tr ...... V [clinicaltrials:NCT01601626]

@en